REGISTER
10 Global Clinical Trials to Watch in H2 2026
BioPharma Dive highlighted 10 key H2 2026 trial readouts spanning oncology, Alzheimer’s, autoimmune disease, vaccines, cardiology and anticoagulation. Key programs include Summit/Akeso’s ivonescimab vs Keytruda in NSCLC, BMS’s Cobenfy for Alzheimer’s psychosis, Celldex’s barzolvolimab in CSU, Moderna/MSD’s intismeran in melanoma, AstraZeneca/Ionis’s eplontersen in ATTR-CM, Biogen’s litifilimab in SLE, Vaxcyte’s VAX-31, Takeda’s zasocitinib, Novartis’s del-desiran and BMS/J&J’s milvexian.

In the first half of 2026, the global biopharmaceutical industry experienced a long-awaited warming. Several large-scale BD transactions emerged, and multiple biotech companies successfully went public and raised substantial funds, signaling renewed market interest in startups that survived the industry downturn.

Meanwhile, companies have made scientific breakthroughs in pancreatic cancer, hepatitis B, and obesity. In fields such as lung cancer, Alzheimer’s disease, and autoimmune diseases, a wave of key data is awaiting disclosure.

On June 29, BioPharma Dive published its list of 10 clinical trials to watch in the second half of 2026. "Pharma Innovation" has compiled and edited the content for readers.

1. Ivonescimab (PD-1/VEGF Bispecific Antibody)

Companies: Summit Therapeutics, Akeso Biopharma

Trial: Harmoni-3

PD-1/VEGF bispecific antibodies are currently one of the most closely watched focuses in oncology drug development. Two years ago, Akeso and Summit released key study data suggesting that ivonescimab was more efficacious than Merck’s Keytruda and other immunotherapies, but subsequent updated overall survival (OS) results clouded the drug’s foreground.

At this year’s ASCO plenary session, the Phase III Harmoni-6 study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC) release latest results showing statistically significant OS benefit, becoming a focal point of the session.

Harmoni-3 is expected to read out results within the year. This is a global head-to-head study comparing ivonescimab plus chemotherapy versus Keytruda plus chemotherapy as first-line treatment for NSCLC, aiming to demonstrate that the combination can delay disease progression and reduce mortality risk. Its results will directly address skepticism about "insufficient global population data." If the Harmoni-3 study is successful, it has the potential to revolutionize the treatment paradigm for NSCLC and raise industry expectations for PD-1/VEGF combination therapy in other tumor types.

2. Cobenfy/KarXT (M1/M4 Agonist)

Company: Bristol Myers Squibb

Trial: ADEPT-2

At the end of 2023, BMS acquired Karuna Therapeutics for $14 billion, gaining its core asset KarXT/Cobenfy (M1/M4 agonist) for schizophrenia. However, the drug’s market performance has been underwhelming, with global sales of $155 million in 2025 and $56 million in Q1 2026. BMS is now conducting new trials to validate KarXT/Cobenfy’s potential in Alzheimer’s disease-related psychosis. In the U.S. alone, there are approximately 7 million Alzheimer’s patients, of whom an estimated 25%–50% develop related psychotic symptoms, representing a substantial market opportunity.

The ADEPT-2 results will determine whether BMS can enter this indication. The readout was expected earlier, but BMS previously cited "irregularities" at a few trial sites, delaying results and causing some unease. Even if ADEPT-2 fails, ADEPT-1 and ADEPT-4 for the same indication are also expected to yield data this year. This series of studies is critical for Cobenfy’s label expansion.

3. Barzolvolimab (KIT Monoclonal Antibody)

Company: Celldex Therapeutics

Trials: Embarq-CSU1, Embarq-CSU2

Celldex Therapeutics, headquartered in New Jersey, is developing barzolvolimab, a KIT (CD117)-targeting monoclonal antibody and one of the world’s most advanced innovative therapies targeting mast cells. Celldex is conducting two Phase III trials in chronic spontaneous urticaria (CSU), with data expected in Q4 of this year.

CSU is an inflammatory disease causing wheals on the skin with severe itching, burning, or swelling. An estimated millions of Americans are affected, and existing treatments such as omalizumab (Xolair) and antihistamines often take weeks to work, with some patients showing no response. The ongoing Phase III trials enroll CSU patients still symptomatic after antihistamines or other biologics, aiming to control itching and wheals within 12 weeks. Early studies suggest barzolvolimab may be more potent, faster-acting, and longer-lasting than existing therapies, but these benefits come with a concern—treatment may lower neutrophil levels. Celldex has faced multiple clinical setbacks before; the Phase III results will determine whether the company can produce a blockbuster. Leerink analysts noted that success would not only bring a novel mechanism therapy for CSU but also open significant commercial opportunities in other mast cell-driven diseases.

4. Intismeran (mRNA Cancer Vaccine) + Keytruda

Companies: Moderna, Merck

Trial: Interpath-001

Intismeran autogene (V940) is a personalized mRNA cancer vaccine co-developed by Moderna and Merck, encoding up to 34 tumor-specific antigens. Upon injection, it activates T cells to produce specific immune responses against tumor antigens for precise tumor cell killing.

Interpath-001 is one of the fastest Phase III personalized mRNA cancer vaccine studies globally, evaluating the efficacy and safety of intismeran plus Keytruda as adjuvant therapy for high-risk melanoma post-surgery, with the primary endpoint of relapse-free survival (RFS). The prior KEYNOTE-942 study head-to-head compared intismeran plus Keytruda versus Keytruda alone in high-risk melanoma patients post-surgery. Latest 5-year follow-up data showed that compared with Keytruda alone, the combination reduced the risk of recurrence or death by 49%, reduced the risk of distant metastasis or death by 59%, and showed an improving trend in OS.

Interpath-001 is significant for both Merck and Moderna. Merck aims to extend the patent life of its blockbuster Keytruda through combination therapy, while Moderna, after the sharp decline in COVID-19 vaccine sales, urgently needs its oncology business to revive performance. Previous attempts at cancer vaccines for brain tumors, lung cancer, and renal cancer showed encouraging early results but failed in pivotal trials. If Interpath-001 succeeds, it could propel intismeran to become the world’s first approved mRNA cancer vaccine and open up possibilities for mRNA vaccines in NSCLC, bladder cancer, renal cell carcinoma, and other solid tumors.

5. Eplontersen (TTR-Targeting ASO Drug)

Companies: AstraZeneca, Ionis

Trial: Cardio-TTRansform

Eplontersen is a GalNAc-conjugated antisense oligonucleotide (ASO) drug targeting transthyretin (TTR) mRNA, originally developed by Ionis and co-developed and commercialized by AstraZeneca. In December 2023, eplontersen received FDA approval for hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTR-PN).

The Cardio-TTRansform study aims to evaluate the efficacy and safety of eplontersen in transthyretin amyloid cardiomyopathy (ATTR-CM). A key design feature allows eplontersen to be combined with TTR stabilizers (including tafamidis and acoramidis), and does not exclude patients who have received prior TTR stabilizer therapy. TTR stabilizers are currently the foundation of standard of care (SOC) for ATTR-CM; success would establish a new SOC.

If the ATTR-CM indication is unlocked, eplontersen’s market potential is substantial. For this indication, Pfizer, BridgeBio, and Alnylam each have an approved drug—Pfizer’s tafamidis has annual sales exceeding $6 billion, Alnylam’s Amvuttra has surpassed $2 billion, and BridgeBio’s Attruby is also considered to have blockbuster potential.

6. Litifilimab (BDCA2 Monoclonal Antibody)

Company: Biogen

Trials: TOPAZ-1, TOPAZ-2

Litifilimab is a monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2). BDCA2 is highly expressed on plasmacytoid dendritic cells (pDCs), an upstream immune cell type. BDCA2 monoclonal antibodies can inhibit pDCs, thereby indirectly suppressing the type I interferon (IFN-I) pathway, which is a core pathogenesis mechanism in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).

Biogen is conducting three large-scale trials of litifilimab for different types of lupus. TOPAZ-1 and TOPAZ-2 for active SLE are expected to read out results this year. Currently, the only approved biologics for SLE are GSK’s belimumab (BAFF inhibitor) and AstraZeneca’s anifrolumab (IFNAR1 monoclonal antibody), but due to the heterogeneity of SLE’s mediating pathways, significant unmet needs remain. Litifilimab differs from these two in that its target BDCA2 is an upstream target, theoretically capable of suppressing IFN and multiple inflammatory cytokines at the source.

Over the past few years, Biogen has been seeking growth beyond neuroscience, and litifilimab is one of its key bets. Jefferies analysts noted that if litifilimab is approved for SLE and CLE, it could "easily become a blockbuster," predicting peak sales exceeding $2 billion.

7. VAX-31 (31-Valent Pneumococcal Conjugate Vaccine)

Company: Vaxcyte

Trial: Opus-1

Vaxcyte, headquartered in California, focuses on next-generation pneumococcal conjugate vaccines (PCV). VAX-31, its core product in development, covers 31 serotypes of Streptococcus pneumoniae and is one of the highest-valency PCVs currently in clinical stages.

Pneumococcal infection can cause pneumonia and meningitis, which can be life-threatening. For years, the pneumococcal vaccine market has been dominated by Pfizer’s Prevnar series, with the latest product updated to 20-valent. In 2025, Prevnar series global sales approached $6.5 billion. Merck and GSK have attempted to capture market share but have failed to shake Pfizer’s leadership.

VAX-31 is considered the most formidable competitor to Prevnar’s market position. In Phase I/II studies in adults, VAX-31 generated immune responses to all 31 planned serotypes and showed non-inferior immune responses to all 20 serotypes covered by Prevnar, with superior responses for several serotypes. Opus-1 is a Phase III non-inferiority study in adults evaluating whether VAX-31 is non-inferior to existing PCVs (20-valent Prevnar and 21-valent Capvaxive), with results expected in Q4 of this year.

8. Zasocitinib (TYK2 Inhibitor)

Company: Takeda

Trials: NCT06254950, NCT06233461

TYK2 belongs to the JAK family. TYK2 allosteric inhibitors, with superior selectivity over traditional JAK1/2/3 inhibitors, are a current hotspot in autoimmune drug development. BMS’s deucravacitinib (Sotyktu) is the only approved TYK2 allosteric inhibitor, with approved indications for moderate-to-severe plaque psoriasis and expanding to psoriatic arthritis.

Takeda’s second-generation highly selective TYK2 allosteric inhibitor zasocitinib is one of the strongest competitors. In a head-to-head psoriasis study, zasocitinib demonstrated superior overall skin clearance rates compared to deucravacitinib. Of greater interest are two Phase II trials in inflammatory bowel disease (IBD), targeting Crohn’s disease and ulcerative colitis respectively.

Current mainstream IBD targeted therapies include IL-23 inhibitors, TNF-α inhibitors, and JAK inhibitors, with IL-23 inhibitors considered the best balance of efficacy and safety for long-term treatment. TYK2 inhibitors act at a key node of the IL-12/IL-23 pathway, functionally inhibiting the IL-23-mediated Th17 inflammatory axis, and are regarded as the "strongest competitor" to IL-23 inhibitors, with the added advantage of oral administration. Deucravacitinib’s Phase II IBD trial did not meet its primary endpoint, placing high hopes on zasocitinib.

9. Del-desiran (DM1 Gene Therapy)

Company: Novartis

Trial: Harbor

Novartis acquired Avidity Biosciences last year for $12 billion, one of the company’s largest acquisitions ever. The core assets acquired were Avidity’s antibody-oligonucleotide conjugate (AOC) delivery platform and three late-stage gene therapies for myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD).

The gene therapy for DM1, del-desiran, has entered global Phase II/III clinical trials. In DM1 patients, the DMPK gene mRNA exhibits CTG repeat expansions, forming toxic RNA and causing abnormal RNA splicing, ultimately leading to DM1’s multisystem symptoms. Del-desiran, developed on the AOC platform, targets DMPK gene mRNA to intervene at the source, while conjugated to a transferrin receptor 1 (TfR1) antibody—a protein highly expressed in skeletal muscle and myocardium. This conjugation mechanism enables more precise delivery to muscle tissue, improving in vivo delivery efficiency. Novartis previously projected that if approved, del-desiran could reach peak annual sales of $6 billion.

10. Milvexian (FXI Inhibitor)

Companies: Bristol Myers Squibb, Johnson & Johnson

Trials: Librexia-AF, Librexia-Stroke

The anticoagulation market is vast. Despite a relatively丰富 array of options, how to reduce bleeding risk while ensuring efficacy remains an unsolved challenge. Traditional direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban inhibit FXa or thrombin, but these targets are involved in both pathological thrombosis and physiological hemostasis, so bleeding risk persists.

Milvexian, co-developed by BMS and J&J, is a selective coagulation factor XI (FXI) inhibitor that theoretically inhibits only pathological thrombosis while preserving normal hemostasis as much as possible, potentially achieving "safer anticoagulation". Milvexian is in two Phase III trials: (1) in atrial fibrillation patients, to demonstrate non-inferiority to apixaban with reduced bleeding risk; and (2) in prior stroke patients, to show superior reduction of recurrent stroke risk when combined with standard antiplatelet therapy versus standard antiplatelet therapy plus placebo.

Although milvexian previously failed in acute coronary syndrome, leading BMS and J&J to abandon development in that indication, industry analysts note that anticoagulants are more commonly used for stroke prevention in atrial fibrillation patients. BMS and J&J maintain that if Phase III succeeds, milvexian’s peak sales could reach "multiple billions of dollars".

Source: 10 clinical trials to watch in the second half of 2026. BioPharma Dive.

0
0
Loading